The new assessment by University of New South Wales researchers reframes the debate on vaping cancer risk: the review finds that inhalation from nicotine e-cigarettes produces changes in oral and lung tissues associated with cancer, even though long-term population data remain limited.
What is not being told about vaping cancer risk?
Verified fact: Researchers at the University of New South Wales in Sydney led a detailed assessment of reviews of evidence from animal studies, human case reports and laboratory research published between 2017 and 2025, and published their synthesis in the journal Carcinogenesis. Adjunct Prof Bernard Stewart said, “There is no doubt that the cells and tissues of the oral cavity, the mouth and the lungs are altered by inhalation from e-cigarettes. ”
Verified fact: The review did not estimate how many people will develop cancer from vaping. Investigators noted that modern e-cigarettes were invented in the early 2000s, so there is insufficient long-term data on large numbers of vapers who later developed cancer. The review highlighted complicating factors: many people who vape also smoke, making it difficult to isolate the effects of vaping alone.
Analysis: The central omission is not new data but duration and scale. The review replaces long-term incidence estimates with biological markers — changes known to precede cancer — to assess risk earlier than decades-long epidemiology would allow. That shifts the public-health question from counting cases today to acting on early mechanistic signals.
How does Vaping Cancer Risk appear in the evidence?
Verified fact: The review identified early warning signs strongly linked to cancer risk, including DNA damage and inflammation. It cited animal studies in which mice exposed to e-cigarette vapour developed lung tumours at greater rates than unexposed mice, and it included human case reports from dentists who observed oral cancer in people who had only vaped and had never smoked. Lead author Associate Prof Freddy Sitas noted a historical parallel: recognizing smoking as a cause of lung cancer took many decades of accumulating evidence.
Verified fact: Calvin Cochran, a research fellow at the University of Otago’s Department of Public Health in New Zealand, emphasised the volume of studies assessed in past public-health reckonings by saying that nearly 8, 000 studies were ultimately examined in the earlier smoking-cancer work and warned against dismissing early signs on vaping.
Analysis: The body of evidence reported in the review is heterogeneous — animal experiments, laboratory assays, and case reports — yet consistently points to biological changes that epidemiology would predict precede clinical disease. The review’s methodological choice to evaluate pre-carcinogenic changes is an acknowledgement that waiting for long-term cohort data will delay actionable findings by years or decades.
Who benefits, who is implicated, and what should be done next?
Verified fact: The review’s authors concluded that, on the basis of the accumulated knowledge they assessed, e-cigarettes are likely to cause lung cancer and oral cancer, while also stating they cannot yet quantify the eventual burden. Associate Prof Freddy Sitas said the historical experience with smoking counsels caution about granting vaping the same presumption of safety once afforded tobacco.
Analysis: Stakeholders who have treated vaping as a safer alternative face a difficult pivot: the evidence flagged by the review undermines assumptions of safety even if it does not provide immediate incidence numbers. Policymakers and regulators are left with a choice between acting on mechanistic and animal data now or waiting for population-level cancer outcomes that will emerge only after many more years of use.
Accountability and next steps: The review urges regulators to act now rather than wait decades for definitive incidence data. That call rests on lab and animal findings, dentist case reports, and the documented presence of DNA damage and inflammation in exposed tissues. Transparency about these biological signals, stronger surveillance of vapers who have never smoked, and regulatory review of product ingredients and marketing are the pathways the review places on the table.
Verified fact: The authors emphasise uncertainty about magnitude while asserting likely causation; they and external public-health researchers warn that failing to take emerging evidence seriously risks repeating past delays in recognizing tobacco’s harms.
Analysis: Measured, evidence-based regulatory response can be informed by the review’s focus on early carcinogenic indicators rather than waiting for decades of cohort outcomes. That approach prioritises prevention when mechanistic evidence suggests plausible harm.
As regulators consider these findings, the public deserves clear updates on the implications of the review and why early biological signals matter. The debate should no longer assume vapes are harmless: the review reframes that assumption around documented mechanisms and early warnings about vaping cancer risk.
